A 68-year-old with HFrEF and CKD stage 3 is started on finerenone. Finerenone differs from spironolactone's aldosterone antagonism in HF management primarily because finerenone:

• A Is a non-steroidal selective mineralocorticoid receptor antagonist with lesser off-target androgenic effects and demonstrated cardiorenal protection in diabetic kidney disease ✓
• B Blocks aldosterone synthesis rather than receptor binding, preventing both cardiac and renal aldosterone effects
• C Has higher potassium-sparing potency than spironolactone, making it safer in hyperkalemia-prone CKD
• D Also inhibits endothelin-A receptor providing additional anti-fibrotic action in cardiomyocytes

Explanation

Finerenone is a novel non-steroidal, selective mineralocorticoid receptor antagonist (MRA). Unlike steroidal MRAs (spironolactone, eplerenone), finerenone has a distinct binding mode causing different MR conformational changes and selective co-activator dissociation, resulting in potent anti-fibrotic effects in heart and kidney with less off-target interaction with androgen, glucocorticoid, and progesterone receptors (avoiding gynecomastia, menstrual irregularities). FIDELIO-DKD and FIGARO-DKD trials demonstrated cardiorenal protection in type 2 diabetes with CKD specifically. It does not block aldosterone synthesis.

Reference: KD Tripathi, Essentials of Medical Pharmacology, 8th ed.

High-yield for: NEET PGINI-CETNExTFMGEUSMLEPLABMRCP

Written and medically reviewed by the StethoPrep medical team.